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Abstract
The Arf tumor suppressor acts as a sensor of oncogenic signals, countering aberrant proliferation in large part via activation
of the p53 transcriptional program, though a number of p53-independent functions have been described. Mounting
evidence suggests that, in addition to promoting tumorigenesis via disruptions in the homeostatic balance between cell
proliferation and apoptosis of overt cancer cells, genetic alterations leading to tumor suppressor loss of function or
oncogene gain of function can also incite tumor development via effects on the tumor microenvironment. In a transgenic
mouse model of multi-stage pancreatic neuroendocrine carcinogenesis (PNET) driven by inhibition of the canonical p53 and
Rb tumor suppressors with SV40 large T-antigen (Tag), stochastic progression to tumors is limited in part by a requirement
for initiation of an angiogenic switch. Despite inhibition of p53 by Tag in this mouse PNET model, concomitant disruption of
Arf via genetic knockout resulted in a significantly accelerated pathway to tumor formation that was surprisingly not driven
by alterations in tumor cell proliferation or apoptosis, but rather via earlier activation of the angiogenic switch. In the setting
of a constitutional p53 gene knockout, loss of Arf also accelerated tumor development, albeit to a lesser degree. These
findings demonstrate that Arf loss of function can promote tumorigenesis via facilitating angiogenesis, at least in part,
through p53-independent mechanisms.
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Introduction
The ARF (alternative reading frame; p14
ARF in human, p19
Arf
in mouse) tumor suppressor serves as a sensor of hyper-
proliferative signals, resulting in p53-dependent growth arrest
and apoptosis [1,2,3]. While ARF is not expressed at appreciable
levels in most normal tissues, oncogene activation triggers its
expression [4], resulting in inhibition of the MDM2 ubiquitin
ligase and stabilization of p53 [5]. Inhibition of the p53 pathway,
most commonly via mutations in p53 itself, inactivation of ARF,o r
amplification of MDM2 is thought to be a critical step in the
pathogenesis of most human cancers [6]. Although mutation of
p53 and ARF in tumors are for the most part mutually exclusive
events [7], mounting evidence suggests that the relationship
between p53 and ARF is not strictly linear and points to p53-
independent tumor suppressor functions of ARF [8,9]. Initial in
vivo evidence for a potential disconnect between ARF and p53
came from the finding that combined p19
Arf and p53 deficiency in
mice results in the emergence of a tumor spectrum consisting of a
wider range of tumor types than in mice lacking either gene alone
[9]. Subsequently, a study in the DMBA/TPA two-step mouse
skin carcinogenesis model revealed an accelerated growth rate of
papillomas in a p19
Arf-deficient compared to a p53-deficient
genetic background [10]. Similarly, p19
Arf but not p53 deficiency
facilitated melanoma development in a transgenic mouse model
through relief of a p53-independent senescence pathway [11]. A
more recent study suggested a context-dependence to the outcome
of p19
Arf loss during oncogenesis in the setting of Pten-deficiency, in
that p19
Arf loss imparted a partial inhibitory function during
prostate carcinogenesis, but abolished senescence and promoted
hyperproliferation and transformation of mouse embryo fibro-
blasts. In both settings the differential outcome of p19
Arf loss
occurred without effects on p53 activity [12].
In a transgenic mouse model of multi-stage pancreatic
neuroendocrine carcinogenesis (PNET), RIP-Tag2, expression of
the SV-40 T-antigen (Tag) in pancreatic b cells leads to inhibition
of the tumor suppressors p53 and Rb, promoting a temporally
defined yet stochastic multi-stage pathway to tumorigenesis.
Despite oncogene expression in all ,400 mouse pancreatic islets,
secondary events are required for progression to each step of the
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12454pathway to tumors [13,14]. The majority, but not all normal islets
develop into hyperplastic/dysplastic lesions throughout the
approximate 14 week lifespan of RIP-Tag2 mice. Similarly, only
a subset (,15–20%) of hyperplastic islet lesions undergo an
angiogenic switch, and only a fraction (,25%) of these angiogenic
islets subsequently progress into solid tumors. Promotion of the
hyperplastic switch is thought to be in part mediated by the
growth/survival factor, IGF-II, as its expression is induced
concomitant with the onset of b-cell hyper-proliferation [15]. A
more recent study has identified an association between micro-
RNA expression signatures and the different RIP-Tag2 tumor-
igenesis stages, with the implication that alterations in the
expression of these miRNAs could be playing a role in driving
these ‘‘switches’’ [16].
We sought in this investigation to ascertain whether Arf had
p53-independent functions in suppressing tumor progression in the
RIP-Tag2 PNET model, via crosses to mice carrying a genetic
knock-out of Arf. A previous study showed that genetic knockout of
p53 in this model did not result in an accelerated pathway to
tumor formation, and in fact, beta tumor cell proliferation was
reduced, likely a consequence of destabilization of the SV-40 large
T antigen oncogene, to which it binds [17]. In contrast, we
demonstrate here that loss of Arf significantly accelerates tumor
formation, via facilitating the angiogenic switch. These studies
provide in vivo evidence for p53-independent functions of Arf and
suggest a novel role for Arf as a suppressor of tumor angiogenesis.
Results
Knockout of Arf accelerates RIP-Tag2 tumor progression
without significant effects on tumor cell apoptosis/
proliferation
Consistent with the known induction of p19
Arf in response to
oncogenic signals [4], Arf mRNA expression was found to be
induced in SV-40 Tag expressing hyperproliferative islets
compared to normal islets, with a further increase with progression
to angiogenic lesions and solid tumors in RIP-Tag2 mice (Figure 1).
To determine whether Arf might be suppressing tumorigenesis in
the setting of p53 inhibition, we assessed the effects of genetic
knockout of Arf on this pathway. Remarkably, loss of Arf resulted
in a very significant, nearly 5-fold increase in tumor burden
(Figure 2A, p,0.0001); there was, in addition, a 1.8-fold increase
in tumor number (Figure 2B, p=0.002). Heterozygous loss of Arf
also resulted in a significant increase in tumor burden (p,0.001)
and tumor number (p=0.02) compared to Arf wild-type RIP-Tag2
mice. Loss of the wild-type Arf allele did not occur in any of the
Arf
+/2 tumors examined (Figure S1).
Given the previously demonstrated ability of ARF to induce cell
cycle arrest and apoptosis independently of p53 [9,18,19,20,21],
we examined for changes in apoptosis and proliferation as assessed
by TUNEL labeling and BrdU incorporation, respectively, in pre-
neoplastic and tumor lesions from RIP-Tag2; Arf
+/+ and Arf
2/2
mice. Surprisingly, we were unable to detect any significant effect
of loss of Arf on either of these parameters at any of the RIP-Tag2
stages (Figure 2C, D). To ensure that we did not overlook subtle
effects on cell cycle regulation/proliferation, in addition to the
BrdU incorporation assay, which measures the percentage of cells
in S-phase, we also assessed the proliferative index by immunos-
taining for phospho-histone H3, a marker for cells in M-phase. In
agreement with the BrdU-incorporation assay, no significant
difference in the percentage of cells in M-phase was observed upon
loss of Arf (Figure S2). Furthermore, stable knockdown of Arf using
an Arf targeting shRNA in a cell line derived from a wild-type RIP-
Tag2 tumor had no effect on growth of the cancer cells in vitro
(Figure 3).
Loss of Arf facilitates the angiogenic switch
To investigate how knockout of Arf might be accelerating tumor
growth without alterations in b-cell proliferation or apoptosis, we
assessed whether loss of Arf could be affecting any of the inherent
barriers that limit transition of oncogene expressing b-cells in
pancreatic islets through the different steps to tumor formation.
Despite expression of the Tag oncogene in the developing
pancreas beginning at embryonic day 9, there is a delay in the
sporadic initiation of islet hyperproliferation by several weeks. To
determine whether loss of Arf could facilitate an earlier initiation
of the hyperplastic switch, we examined the percentage of
hyperproliferative islet lesions (as determined by staining with
the Ki67 proliferation marker) at both 3- and 5-weeks of age in
RIP-Tag2; Arf
+/+ and Arf
2/2 mice. No significant difference in the
percentage of hyperproliferative islets was observed at either of
these stages (Figure 4A), though at 5-weeks of age, islets from RIP-
Tag2; Arf
2/2 mice were on average larger in size (Figure S3A; 1.5-
fold increase; p=0.007). The increased lesion size was not a result
of increased cell size as the number of cells/area was nearly
identical between the two groups (Figure S3B).
We next assessed the effects of Arf knockout on the frequency of
angiogenic switching. In contrast to the negligible impact on the
incidence of islet hyperplasias, the number of red, hemorrhagic
angiogenic islets was significantly increased (by approximately
30%) in 8 week-old RIP-Tag2; Arf
2/2 mice compared to RIP-Tag2;
Arf
+/+ littermates (Figure 4B; p=0.01). In addition, while the
appearance of solid tumors was very rare at 8 weeks in RIP-Tag2;
Arf
+/+ mice (tumors present in 4/11 mice; average of ,1 tumor/
mouse), small tumors were found in nearly all RIP-Tag2; Arf
2/2
mice analyzed at this age (average of ,2.5 tumors/mouse;
Figure 4C, p,0.0001). Of note, in the scoring for hyperplastic
lesions at the 5 week time point, occasional islets exhibiting the
typical hemorrhagic features/blood islands of angiogenic islets
[22,23] were observed, with a trend towards a higher incidence in
the Arf
2/2 compared to Arf
+/+ mice; however, this difference was
not statistically significant at this time point (Figure S3C). Thus, in
this multi-stage model, loss of Arf accelerates tumor formation, at
least in part, via facilitating the angiogenic switch.
Figure 1. Expression of Arf mRNA during RIP-Tag2 tumor
progression. The mRNA levels of Arf were assessed using quantitative
RT-PCR on cDNA generated from RNA pools of normal non-transgenic
islets, and hyperplastic islets, angiogenic islets (isolated islets from 5–10
mice were pooled), and tumors (equal amounts of RNA isolated from 10
tumors from at least 5 mice pooled) from RIP-Tag2 mice. Gene
expression normalized and plotted relative to mGus expression.
doi:10.1371/journal.pone.0012454.g001
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the vascular phenotype
To further explore the nature of the increased angiogenic
phenotype in the RIP-Tag2; Arf
2/2 mice, we next assessed the
phenotype of the angiogenic vasculature. Despite the increased
number of angiogenic lesions in RIP-Tag2; Arf
2/2 mice, the
resultant lesions did not significantly differ in vascular density or
morphology (vessel thickness, degree of branching) (Figure 5A and
data not shown), or in the degree of pericyte coverage (Figure 5B).
Given previous findings demonstrating a role for MMP-9
expressing neutrophils in promoting the angiogenic switch [24],
we also examined whether loss of Arf expression resulted in
alterations in the incidence of neutrophil recruitment to ‘‘pre-
angiogenic’’ hyperplastic lesions. In both RIP-Tag2; Arf
+/+ and
RIP-Tag2; Arf
2/2 mice, double-immunostaining for the Ki67
proliferation marker and the 7/4 neutrophil marker demonstrated
that approximately 25% of hyperplastic lesions examined (at 5
weeks of age) contained infiltrating neutrophils (in most cases not
more than one 7/4+ cell/islet; data not shown). In addition, no
significant changes in the number of infiltrating MMP-9 and 7/4
double positive cells was observed in angiogenic lesions from 8-wk
old RIP-Tag2; Arf
+/+ and RIP-Tag2; Arf
2/2 mice (data not shown).
Selective Arf knockout in stromal compartment does not
significantly enhance tumor development
Previous studies have demonstrated that Arf
2/2 mice are blind
due to a defect in involution of the hyaloid vasculature in the eye
during development, resulting from an accumulation of Pdgrfrb+
perivascular cells [25,26]. Data implicated both cell autonomous
and non-autonomous effects of loss of Arf on this phenotype [27].
Since RIP-Tag2; Arf
2/2 mice lack Arf expression throughout the
body and not just in tumor cells, we questioned whether loss of Arf
in a non-b-cell type could in part be facilitating the angiogenic
switch and tumor formation. To begin exploring this possibility,
Figure 2. Genetic knockout of Arf accelerates RIP-Tag2 tumor progression without significantly affecting apoptosis/proliferation.
(A,B) Effects of heterozygous and homozygous knockout of Arf on tumor burden (A; *p,0.001, **p,0.0001 compared to Arf+/+; the difference
between Arf+/2 and Arf2/2 mice was not statistically significant) and tumor number (B; *p=0.02, **p=0.002) in 12 week-old RIP-Tag2 mice. Mean
values +/2 SEM from 15 (Arf+/+), 17 (Arf+/2), or 20 (Arf2/2) mice/group are indicated. Mann-Whitney test for statistical significance. (C) Apoptosis,
as determined by TUNEL labeling in hyperplastic islets (Hyp), angiogenic islets (Ang), and tumors (Tum) from Arf
+/+ or Arf
2/2 RIP-Tag2 mice. Mean
values +/2 SEM from graded lesions of 6–7 individual mice of each genotype are indicated. The number of total lesions analyzed for each genotype/
lesion stage are as follows: Arf+/+ (Hyp: n=27; Ang: n=33; Tum: n=14); Arf2/2 (Hyp: n=18; Ang: n=25: Tum: n=22). (D) Proliferation, as measured
by the % of cells with BrdU incorporation in the different stages of islet lesions from 4 individual Arf+/+ (Hyp: n=21; Ang: n=24; Tum: n=12) and
Arf2/2 (Hyp: n=18; Ang: n=22; Tum: n=24) RIP-Tag2 mice.
doi:10.1371/journal.pone.0012454.g002
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stromal compartment of wild-type RIP-Tag2 tumors. Real-time
quantitative RT-PCR analysis on sorted cell compartments from
RIP-Tag2 tumors demonstrated Arf expression, as expected, in the
tumor cell compartment, but not in endothelial cells (CD31+),
immune cells (CD45+), or pericytes (Pdgfrb+) (Figure 6A and S4).
These results are consistent with the notion that induction of Arf
expression is, for the most part, limited to response to oncogenic
signals [4]; however, this analysis did not rule out the possibility of
transient induction of Arf expression in the stromal cell types
analyzed, nor expression in other classes of tumor infiltrating cells
[e.g. Pdgfrb-negative pericytes [28]].
To directly assess the potential role of Arf knockout in the non-
tumor cell compartment in influencing tumor progression, we
performed orthotopic experiments wherein tumor cells derived
from a RIP-Tag2; Arf
+/+ tumor were injected into the pancreas of
immunocompetent Arf
+/+ or Arf
2/2 mice, and tumor size was
measured four weeks later. There was no significant difference in
the average tumor size between tumors formed in Arf
+/+ versus
Arf
2/2 mice (Figure 6B). Combined with our inability to detect Arf
expression in a tumor stromal cell type, these results suggest that
knockout of Arf in the tumor stromal compartment is not likely to
be the predominant driver of the hastened tumor growth observed
upon Arf knockout in RIP-Tag2 mice. Since it is unclear whether
the mechanism of angiogenesis induction in orthotopically injected
tumor cells follows a similar pathway as angiogenesis induced in
endogenous pre-neoplastic lesions, the possibility remains that the
lack of observed effect could in part be reflecting such differences.
Knockout of Arf accelerates tumor formation via both
p53-dependent and independent mechanisms
Since p53 has been shown to be quantitatively sequestered by
SV-40 Tag and its transactivation activity is demonstrably
inhibited in b-cells of RIP-Tag2 mice [17], we suspected the
majority of effects observed upon knockout of Arf to be p53-
independent. Nevertheless, we proceeded to verify the p53-
independence of the Arf knockout phenotype by analyzing the
effects of Arf knockout in a p53-null genetic background. As in the
p53-wild-type background, Arf knockout in RIP-Tag2; p53
2/2
mice resulted in a significantly increased (2.4-fold) tumor burden at
12 weeks of age compared to Arf
+/+ littermates (Figure 7A;
p,0.001), as well as a significant 30% increase in the number of
angiogenic lesions (Figure 7C; p=0.04) and small tumors
(Figure 7D; p=0.002) at 8 weeks of age, confirming that these
effects are at least in part p53-independent. However, it should be
noted that the magnitude of the impact of Arf knockout on tumor
burden (at 12 weeks) and tumor number (at 8 weeks) was not as
dramatic as in the RIP-Tag2; p53-wild-type mice (Figure 2). In
addition, although tumor initiation occurred earlier in RIP-Tag2;
p53
2/2; Arf
2/2 compared to RIP-Tag2; p53
2/2; Arf
+/+ mice, by
12 weeks of age, no difference in tumor number was detected
between mice of these genotypes (Figure 7B), suggesting that both
p53-dependent and independent functions of Arf cooperate to
suppress the angiogenic switch and tumor progression in this
multi-stage carcinogenesis model.
In an attempt to identify a molecular mechanism for the
increased angiogenic switching frequency in Arf-null RIP-Tag2
mice, we analyzed expression of an array of angiogenesis-related
genes by real-time PCR. We did not, however, identify any
angiogenic regulatory genes that were convincingly altered at the
transcriptionallevelinwholetumorsorangiogenicisletsupon lossof
Arf (data not shown and Figure S5A). In light of recent studies
demonstratingaroleforArfinribosomebiogenesis[29] and inpost-
transcriptional control of VEGF expression [30], we assessed
possible changes in VEGF expression at the protein level upon loss
of Arf. Although VEGF protein levels were modestly elevated in
RIP-Tag2 tumors in the p53-null genetic background (35%
increase; p=0.02), we found that in this genetic context, loss of
Arf did not result in altered levels of total VEGF protein (Figure
S5B). In addition, immunostaining for VEGF did not reveal any
obvious changes in VEGF expression/localization in the different
pre-neoplastic islet lesions in the Arf-null RIP-Tag2 mice (Figure
S5C). Thus, there is no indication that the accelerated angiogenesis
resulting from loss of Arf involves alteration in VEGF biosynthesis.
Discussion
Inactivation of the ARF/p53 pathway is a critical event in the
majority of human cancers, serving to lift restraints on oncogenic
Figure 3. Knockdown of Arf does not affect growth of SV-40 Tag oncogene expressing b-tumor cells. Tumor cells were stably transduced
with a non-silencing (NS) or Arf silencing shRNA. (A) Knockdown of Arf protein expression by the Arf targeting shRNA. b-actin protein levels indicated
as a control for protein load. (B) Effect of Arf knockdown on tumor cell growth in vitro. Mean values +/2SEM from three independent experiments
performed in triplicate are indicated.
doi:10.1371/journal.pone.0012454.g003
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activities of p53 in mediating cell cycle arrest, apoptosis and
senescence, p53 can also function in maintaining tumor dormancy
via suppression of angiogenesis [32]. In a multi-stage carcinogen-
esis model in which p53 is functionally inhibited by SV-40 Tag, we
demonstrate that p19
Arf can also modulate the angiogenesis
program, at least in part via p53-independent mechanisms.
Genetic ablation of Arf in RIP-Tag2 mice resulted in a significant
acceleration of the tumorigenesis pathway, which was associated
with an increased frequency of islets undergoing an angiogenic
switch and earlier tumor formation. Notably, the hyperprolifera-
tive switch was not affected, nor were proliferation/apoptosis
indices at any stage of the pathway to tumor formation.
Despite the increased frequency of angiogenic switching, the
vasculature within the resultant angiogenic lesions did not significantly
differ phenotypically between RIP-Tag2; Arf
+/+ and Arf
2/2 mice,
consistent with previous studies in this model wherein altered
angiogenic switching frequencies occurred without concomitant
changes in vessel morphology or tumor cell apoptosis/proliferation
upon genetic knockout of MMP-9 [33] or neutrophil ablation [24].
The absence of global differences in the degree of neutrophil
recruitment to pre-angiogenic lesions in RIP-Tag2; Arf
2/2 compared
to Arf
+/+ mice suggests that Arf may modulate angiogenesis via an
alternative mechanism.However, due to the multi-focal and stochastic
nature of this tumor model, in which only approximately 15–20%
(based on a total of 400 islets/mouse) of hyperplastic lesions will
become ‘‘angiogenic’’ (this frequency is increased by just a few % in
Arf
2/2 mice) the possibility remains that undetected transient
alterations in neutrophils in a small subset of lesions could be
accounting for the increased incidence of angiogenic switching.
While it is currently unclear what specific signal(s) drives the
initial recruitment of inflammatory cells and initiation of the
angiogenic switch, the current paradigm suggests that a disruption
in the balance between endogenous pro- and anti-angiogenic
Figure 4. Effects of Arf knockout on the hyperplastic and angiogenic switches during RIP-Tag2 tumorigenesis. (A) Effects on the
hyperplastic switch. Islets from Ki67-stained sections from 3- or 5-week old mice were scored as ‘‘normal’’ (no hyperproliferation) or hyperplastic.
Values represent the distribution of the different islet subclasses within the indicated genotypes. For 3-week mice, 60 (Arf+/+) and 58 (Arf2/2) islet
lesions were scored on sections from 3 mice/group; for 5-week old mice, 166 (Arf+/+) and 231 (Arf2/2) islet lesions were scored on sections from 3–4
mice/group. The distribution of islet types was not significantly different between the two genotypes at either time point (Fisher’s exact test; 5 week
timepoint: p=0.06). Representative Ki67-stained hyperplastic lesions (from 3-week old RIP-Tag2 mice) of the indicated Arf genotypes are depicted on
the right. (B, C) Effects on the angiogenic switch and tumor initiation. The number of red, angiogenic lesions (B) and tumors (C) was calculated from
11 (Arf+/+)o r1 5( Arf2/2) 8-week old RIP-Tag2 mice of the indicated genotypes. Mean values 6SEM are indicated. Mann-Whitney test for statistical
significance; *p=0.01, **p,0.0001.
doi:10.1371/journal.pone.0012454.g004
Arf Loss and Angiogenic Switch
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functions of ARF that have been described to date [8], several can
be envisioned to potentially impact the angiogenic switch. In
particular, NF-kB and c-Myc, both of which have been implicated
in regulating angiogenesis via their effects on expression of pro-
inflammatory mediators [35,36,37], have been identified as p53-
independent targets of ARF [38,39]. Additionally, nucleolar
sequestration of the major inducer of angiogenesis, HIF-1a by
ARF has been demonstrated to regulate its transcriptional activity
[40]. Further, a recent complementary study by Kawagishi et al.
suggested a p53-independent role for ARF in suppressing tumor
angiogenesis via post-transcriptional control of VEGF-A expres-
Figure 5. Effects of Arf knockout on the angiogenic vasculature. (A) Visualization of the vasculature in angiogenic lesions from 8-week old
RIP-Tag2 mice of the indicated genotypes by immunostaining for Meca32 (red). Representative Meca32/DAPI (blue) merged images are shown. Vessel
density was calculated by measuring the area occupied by Meca32+ vessels; values represent the mean 6SEM calculated from analyzing 16–20
angiogenic lesions from 4 individual mice of each genotype. (B) Double immunostaining for Meca32 (endothelial cells, red) and NG2 (pericytes,
green) was performed to analyze the degree of pericyte coverage within the angiogenic vasculature from 8-week RIP-Tag2 mice of the indicated
genotypes. Bars, 20 mm.
doi:10.1371/journal.pone.0012454.g005
Figure 6. Arf expression and the effect of knockout in tumor stromal compartment. (A) Expression of Arf in the different constituent RIP-
Tag2 tumor cell types. Real-time quantitative RT-PCR was performed on mRNA isolated from FACS sorted cells from RIP-Tag2 tumors [ECs (endothelial
cells), ICs (immune cells), T/OCs (tumor/other cells)]. Expression levels plotted relative to L19 expression. (B) Effect of Arf knockout on tumor
development of orthotopically transplanted tumor cells. 1610
5 tumor cells derived from a RIP-Tag2; Arf
+/+ tumor were injected into the pancreas of
Arf
+/+ or Arf
2/2 mice and allowed to grow for 4 weeks. Values represent the average tumor volume (+SEM) calculated from tumors isolated from 12
individual mice of each of the indicated genotypes. The difference between the values did not achieve statistical significance (Mann-Whitney test;
p=0.1).
doi:10.1371/journal.pone.0012454.g006
Arf Loss and Angiogenic Switch
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protein levels were not significantly altered by loss of Arf. Thus, we
infer that increased expression levels of VEGF do not underlay the
earlier angiogenic switching, although we cannot exclude possible
alterations in VEGF bioavailability, mediated for example by
increased matrix degrading proteolytic activity.
A potential role for ARF in the process of vasculogenesis and/or
angiogenesis had previously been postulated [8], stemming from the
demonstration that Arf can regulate vascular development in the
mouse eye [25], one of the only described functions of ARF aside
from tumor suppression. A mechanism whereby loss of Arf enhances
Pdgf signaling, resulting in an excessive proliferation and accumula-
tion of Pdgfrb+ perivascular cells was proposed to explain the
vascular defect resulting in blindness in Arf
2/2 mice. While there
were no measurable alterations in pericyte accumulation in the
vasculature of RIP-Tag2; Arf
2/2 angiogenic lesions, the possibility
remains that the initial recruitment of Pdgrb+ perivascular cells to the
neovasculature could be stimulated either directly or indirectly (e.g.
via secretion of an as yet to be identified pro-angiogenic factor from
Arf-null pre-neoplastic/tumor cells) by loss of Arf.
Expansive tumor development/growth requires not only
deregulation of cell growth and survival signals, but also involves
significant alterations to the incipient tumor microenvironment. In
particular, the formation of a blood supply is critical for tumor
growth and metastasis. Emerging evidence suggests that oncogenes
and tumor suppressors can influence tumor development not only
via cell-autonomous functions in regulating proliferation/apopto-
sis but also via direct modulation of angiogenesis regulators. The
Myc oncogene has been shown to regulate angiogenesis via direct
induction of the pro-inflammatory mediator, IL-1b, which
promotes MMP activation and release of sequestered VEGF from
the extracellular matrix [41]. Ras, via activation of Myc, can
activate angiogenesis via repression of the angiogenesis inhibitor,
thrombospondin-1 [42]. Similarly, tumor suppressor p53 has been
shown to positively regulate thrombospondin-1 expression [43,44],
as well as the production of the anti-angiogenic collagen-derived
fragments endostatin and tumstatin [45]. We herein uncover a role
for p19
Arf in limiting the tumor angiogenic switch, demonstrating
that loss of Arf expression promotes the angiogenic switch and
hastens tumor development, via both p53-dependent and
independent mechanisms, in a model of multi-stage carcinogen-
esis. These findings lend support to the mounting evidence that Arf
can, in part, function as a tumor suppressor independently of its
role in modulating p53 activity, and support the growing paradigm
that oncogenes/tumor suppressors regulate tumor progression not
only via disrupting the balance between homeostatic proliferation/
Figure 7. Arf knockout accelerates tumor progression in part via p53-independent mechanisms. (A, B) Arf knockout in RIP-Tag2; p53
2/2
mice results in an increased tumor burden (A; p,0.0001) without affecting tumor number (B) at 12 weeks of age. Mean values +/2SEM from 19
(p532/2; Arf+/+), or 14 (p532/2; Arf2/2) mice/group are indicated. Mann-Whitney test for statistical significance. (C, D) Increased angiogenic islet
numbers (C; p=0.04) and tumors (D; p=0.002) in RIP-Tag2; p53
2/2; p19
Arf2/2 mice at 8 weeks of age. Mean values +/2SEM from 15 (p532/2; Arf+/+),
or 13 (p532/2; Arf2/2) mice/group are indicated. Mann-Whitney test for statistical significance.
doi:10.1371/journal.pone.0012454.g007
Arf Loss and Angiogenic Switch
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microenvironment to support neoplastic growth.
Materials and Methods
Ethics Statement
All animals were handled in strict compliance with the
requirements of the Animal Welfare Act and Regulations, the
National Institute of Health Guide for the Care and Use of
Laboratory Animals, the Public Health Service Policy on the
Humane Care and Use of Laboratory Animals, and University of
California, San Francisco (UCSF) Policies and Guidelines; mouse
experiments were approved by the UCSF Institutional Animal
Care and Use Committee (IACUC) (Protocol #: AN079620-03A).
Transgenic mice breeding
The generation and characterization of RIP-Tag2 transgenic
mice [13] and p19
Arf knockout mice [1] have been previously
described. p19
Arf2/2 mice were backcrossed 8 generations into
C57BL/6 and intercrossed with RIP-Tag2 mice (C57BL/6) to
generate RIP-Tag2; Arf
+/+, Arf
+/2, and Arf
2/2 mice. For analyses
of the p53-independence of the RIP-Tag2; Arf
2/2 phenotype, mice
were intercrossed with Trp53
2/2 mice [46] in the C57BL/6
background. Littermate controls were used in all experiments.
Tissue preparation
Normal (from non-transgenic C57Bl/6 mice), hyperplastic islets
(from 5–6 wk RIP-Tag2 mice; not red), and angiogenic islets (from
8–10 wk RIP1-Tag2 mice; red, hemorrhagic) were isolated as
previously described [22]. Tumors were microdissected from the
exocrine pancreas of 13–14 wk old RIP1-Tag2 mice. For Taqman
analysis, RNA was isolated using the RNeasy Mini kit including
the on-column DNase digestion step (Qiagen, Valencia, CA) and
cDNA prepared with iScript (BioRad, Hercules, CA). For
histology/immunostaining experiments, mice were anesthetized
with 2.5% avertin and heart perfused with PBS followed by
formalin. Samples were post-fixed for 2 hrs in formalin, followed
by infiltration with 30% sucrose prior to freezing in O.C.T.
medium; for paraffin embedding, tissue was post-fixed overnight at
4uC in zinc-buffered formalin and processed as previously
described [47].
Real-time RT-PCR gene expression analysis
Real-time RT-PCR was performed by the UCSF Cancer
Center Genome Analysis Core on an ABI 7900 machine. For
quantitative real-time PCR analysis, gene expression was exam-
ined using 3–5 ng input cDNA and all reactions were performed
in triplicate; relative expression levels were determined using L19,
Gus and either Gapdh or Cyclophilin as control genes. Quantitative
RT-PCR was performed using the following Taqman assays [all
commercially available from Applied Biosystems (Foster City, CA)
except for p19-Arf (from IDT, Coralville, IA)]: p19-Arf: forward
primer: 59-AGA GGA TCT TGA GAA GAG GGC C-39, reverse
primer: GCA GTT CGA ATC TGC ACC G, probe: 59-/56-
FAM/AAT CCT GGA CCA GGT GAT GAT GAT GGG/36-
TAMSp/-39; PDGFR-b: Mm00435546_m1; Pecam1/CD31:
Mm00476702_m1 Ptprt/CD45: Mm00448463_m1, Col1a1:
Mm00468761_m1, Vegfa: Mm01281447_m1.
Analysis of RIP-Tag2 tumor burden and pre-tumor stages
For tumor burden and tumor number analysis, tumors (lesions
$1 mm) were microdissected and dimensions measured with a
ruler. Volumes were calculated using the formula for approximat-
ing the volume of a spheroid (volume = width
2 6length 60.52)
and tumor burden calculated as the sum of the volumes of all
tumors per mouse. Statistical significance was determined using
the Mann-Whitney non-parametric t-test. For angiogenic islet
counting, pancreata from 8 week-old mice were dissected, cut into
small pieces, and red, hemmorhagic islets (as described in [22])
were scored underneath a dissecting scope. Hyperplastic islets
were scored by staining paraffin tissue sections from 3 or 5 week-
old mice with a rabbit polyclonal antibody to the Ki67
proliferation marker (clone SP6; Thermo Fisher Scientific,
Fremont, CA). Since due to ongoing islet maturation there is a
significant degree of b-cell proliferation in islets from non-
transgenic mice at 3 weeks of age (compared to minimal b-cell
proliferation at 5 weeks of age), to distinguish physiological
proliferation from SV40 Tag-induced hyperproliferation, the
average percentage of Ki67+ cells in 3-week non-transgenic islets
as well as the average percentage from obviously hyperplastic/
dysplastic islets in 3-week RIP-Tag2 mice was determined and a
cutoff of .30% Ki67+ cells was made to define hyperplastic islets.
Angiogenic islets were scored histologically by the presence of
blood islands/lakes [23] (emptied of blood cells as a result of
vascular perfusion method).
Apoptosis and proliferation assays
TUNEL and BrdU assays were performed on 5 mm paraffin
sections as previously described [47]. The percentage of cells in M-
phase was determined by immunostaining paraffin sections with a
rabbit anti-phospho-Histone H3 antibody (1:1000, Upstate #06-
570, Lake Placid, NY) following antigen retrieval with Citra
solution (BioGenex, San Ramon, CA). For assessment of the
effects of Arf knockdown on growth of b-tumor cells (bTC) in
vitro, the pGIPZ lentiviral shRNAmir delivery system (Thermo
Scientific-Open Biosystems, Huntsville, AL) was used to generate
cells containing a stable knockdown of Arf. A bTC line derived
from a RIP-Tag2; Arf
+/+ tumor (bTC105.2) was infected with
lentivirus expressing the mouse GIPZ shRNAmir clone
V3LHS_646508 for Arf knockdown or a non-targeting shRNAmir
control (according to manufacturer’s instructions). Infected cells
were selected and maintained with 2 mg/ml puromycin. Knock-
down of Arf protein expression was confirmed by disrupting cells
in RIPA buffer containing a protease inhibitor cocktail (Roche)
and immunoblotting equal protein amounts with an antibody
to19
Arf (5-C3, Abcam). 250,000 cells were plated in a 6-well plate
in triplicate and cells were trypsinized and counted on day 2, 4,
and 7 to monitor growth.
Analysis of vasculature
Fixed frozen 10 mm pancreas sections from 8-week old mice
were immunostained with a rat monoclonal anti-MECA-32
antibody (1:200; BD PharMingen, San Diego, CA) to label vessel
endothelial cells in the presence or absence of a rabbit polyclonal
antibody to the NG2 pericyte marker (1:200; Chemicon/
Millipore). Staining was visualized with FITC or Rhodamine
Red-X conjugated secondary antibodies (Jackson ImmunoRe-
search, West Grove, PA). Vessel density and percentage pericyte
coverage of vessels (pixel overlap between MECA-32 and NG2
staining) were determined using MetaMorph software (angiogen-
esis application) on photographs of representative 2006 fields of
angiogenic islets.
Flow cytometry
Tumors were excised from ,14-week old RIP-Tag2 mice and
the major constituent cell types were sorted by FACS as previously
described [48] using the following antibodies to sort out
endothelial cells, inflammatory cells, and pericytes respectively:
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and PDGFRb-PE (eBioscience, San Diego, CA). Cells were sorted
into RLT buffer (Qiagen) containing b-ME and stored at 280uC
until isolation of RNA using the RNeasy Micro Kit (Qiagen).
Orthotopic transplant experiment
Pancreata of either Arf
+/+ or Arf
2/2 mice were injected
orthotopically with 100,000 Arf
+/+ b-tumor cells (bTC105.2) in a
50 ml volume containing a 1:1 mixture of cells resuspended in PBS
and Growth Factor Reduced Matrigel (#356231, BD Biosciences,
Franklin Lakes, NJ). Tumors were excised and measured 4 weeks
post-injection.
VEGF ELISA
VEGF-A concentration was measured using the Quantikine
Mouse VEGF Immunoassay (R&D Systems, Minneapolis, MN).
Tumor extracts containing 5 mg of total protein were analyzed/
well in duplicate following manufacturer’s instructions. VEGF
concentration was determined using SoftMax Pro software.
VEGF Immunohistochemistry
5 mm paraffin sections were stained with a goat polyclonal
antibody that recognizes the mouse 120 and 164 VEGF-A
isoforms (R&D Systems) following antigen retrieval with Antigen
Unmasking Solution (Vector Laboratories). A biotinylated anti-
goat secondary antibody (Jackson ImmunoResearch Laboratories)
in conjunction with the Vectastain ABC Elite system (Vector
Laboratories) and SIGMA FAST
TM DAB (3,39-Diaminobenzidine
tetrahydrochloride; Sigma) was used for visualization. Sections
were counterstained with hematoxylin and images captured using
a 20X objective.
Supporting Information
Figure S1 Maintenance of wild-type Arf allele in tumors from
heterozygous Arf knockout mice. Arf mRNA levels were assessed
by quantitative RT-PCR on cDNA generated from individual
tumors from RIP-Tag2; Arf
+/+ or Arf
2/2 mice. The average Arf
expression levels in tumors from the indicated genotypes are
depicted with a yellow bar. Values represent expression relative to
the L19 control gene.
Found at: doi:10.1371/journal.pone.0012454.s001 (0.20 MB TIF)
Figure S2 Loss of Arf does not alter the percentage of
proliferating cells in RIP-Tag2 islet lesions. The percentage of
cells in M-phase as determined by phospho-histone H3 staining in
hyperplastic and angiogenic islets from RIP-Tag2 mice of the
indicated Arf genotypes. Values represent the mean percentage 6
SEM from graded lesions of 6 mice/genotype. Arf+/+ (Hyp:
n=14; Ang: n=18); Arf2/2 (Hyp: n=10; Ang: n=17).
Found at: doi:10.1371/journal.pone.0012454.s002 (0.50 MB EPS)
Figure S3 Phenotype of islet lesions from 5-week old RIP-Tag2;
Arf+/+ and Arf2/2 mice. (A) Lesion size. Average area/islet
lesion depicted from area measurements taken from $27
individual islets on frozen sections from 3 mice/group.
*p=0.007 (B) Cell size. The number of cells/islet lesion was
counted and the average area/cell calculated. Mean values 6
SEM depicted. (C) Left: Islets in Ki67-stained sections were scored
as ‘‘normal’’ (no hyperproliferation), hyperplastic, or angiogenic.
Values represent the distribution of the different islet subclasses
within the indicated genotypes; Arf+/+ (166 lesions scored from 4
mice), Arf2/2 (231 lesions scored from 3 mice). The differences
in lesion distribution between the two genotypes was not
significant (Chi-squared test; p=0.1). Right: representative H&E
stained image of an early angiogenic lesion in a RIP-Tag2;
Arf2/2 mouse (defined by appearance of blood islands [arrow-
head] resulting from hemorrhagic vasculature, here emptied as a
result of vascular perfusion technique).
Found at: doi:10.1371/journal.pone.0012454.s003 (4.98 MB EPS)
Figure S4 Expression of control genes in RIP-Tag2 sorted cell
populations. Real-time quantitative RT-PCR to assess expression
of the indicated cell type-specific markers was performed on
mRNA isolated from FACS sorted cells from RIP-Tag2 tumors to
assess for purity of the sorted fractions. Expression levels of the
indicated genes (labeled on top of each graph) plotted relative to
L19 expression.
Found at: doi:10.1371/journal.pone.0012454.s004 (0.34 MB TIF)
Figure S5 Effect of loss of Arf on VEGF expression. (A) Vegfa
mRNA levels were measured by quantitative RT-PCR on cDNA
generated from pooled tumor RNA of the indicated genotypes.
Each pool consisted of equal amounts of RNA isolated from at
least 8 tumors derived from 5–7 mice/group. (B) VEGF-A protein
levels as measured by ELISA. Bars represent the average (6 SEM)
concentration of VEGF in RIP-Tag2 tumors of the indicated
genotypes (7–10 individual tumors from 7–8 mice/group were
analyzed in duplicate). *p=0.02 compared to Arf+/+ tumors. (C)
Pancreas sections from 8 or 12-week old RIP-Tag2 mice of the
indicated genotypes were immunostained with an antibody to
VEGF. Representative images (sections from 5 mice/group
analyzed) of different classes of islet lesions are depicted (normal:
left; hyperplastic: middle; angiogenic: right).
Found at: doi:10.1371/journal.pone.0012454.s005 (2.03 MB TIF)
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